— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.
— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.
— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.
— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.
— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.
— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.
— ACST shares gained 0.69% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings Preview: Costco (COST) looks poised to end fiscal 2024 on a high note
Costco Wholesale Corporation (NASDAQ: COST), which operates a chain of membership warehouses, will unveil its fourth-quarter results on the evening of September 26. It has a good track record of
Key takeaways from General Mills’ (GIS) Q1 2025 earnings report
Shares of General Mills, Inc. (NYSE: GIS) gained over 1% on Wednesday after the company’s announcement of its first quarter 2025 earnings results. Revenue came in line with estimates while
GIS Earnings: All you need to know about General Mills’ Q1 2025 earnings results
General Mills, Inc. (NYSE: GIS) reported its first quarter 2025 earnings results today. Net sales decreased 1% year-over-year to $4.8 billion. Organic sales were down 1%. Net earnings attributable to
